<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00721552</url>
  </required_header>
  <id_info>
    <org_study_id>DC2008Pred002</org_study_id>
    <secondary_id>Eudract 2008-004985-25</secondary_id>
    <nct_id>NCT00721552</nct_id>
  </id_info>
  <brief_title>Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism in Males With the Metabolic Syndrome</brief_title>
  <acronym>SPHINX</acronym>
  <official_title>Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism and Beta-Cell Dysfunction in Males With the Metabolic Syndrome X: A Randomized, Placebo-controlled, Double-blind Intervention Study With a 2x2 Factorial Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will assess whether the DPP-inhibitor sitagliptin will ameliorate
      glucocorticoid-induced impairment of glucose metabolism and beta-cell dysfunction and thus
      could be used as a prophylaxis for glucocorticoid-induced diabetes. Therefore the
      investigators will administer in males with the metabolic syndrome 30 mg prednisolone daily
      for two weeks and give simultaneously sitagliptin 100 mg daily. Subjects will undergo at
      baseline and after two weeks of treatment several tests to assess changes in glucose
      metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will conduct a randomized, placebo-controlled, double-blind, 2x2
      factorial-designed intervention trial. The pharmacological intervention for
      prednisolone/prednisolone-placebo is 14 days and for sitagliptin/sitagliptin-placebo 28 days.
      Subjects fulfilling the IDF criteria26 for the metabolic syndrome (aged 35-65; n=60) will be
      randomized to one of four groups: I) prednisolone 30 mg and sitagliptin 100 mg daily; II)
      prednisolone 30 mg and sitagliptin-placebo daily; III) prednisolone-placebo and sitagliptin
      100 mg daily; IV) prednisolone-placebo and sitagliptin-placebo daily. Before and at day 14 of
      treatment subjects will undergo a standardized mixed-meal test in order to assess glucose
      disposal and beta-cell function (by modeling analysis). During these meal tests, plasma
      concentrations of (total and active) GLP-1, GIP, glucagon and additional biomarkers will be
      assessed. A combined hyperglycemic-euglycemic clamp will be performed at baseline and at day
      13 of treatment to assess insulin sensitivity and insulin secretion. During the euglycemic
      clamp adipose tissue and muscle biopsies will be obtained, both in fasting and under
      hyperinsulinemic conditions. At baseline and at day 28 of treatment, a 7-point OGTT will be
      performed to assess time to restoration of glycemic control. Body composition, body fat
      distribution and liver fat content, measured by respectively bio-impedance analysis and
      magnetic resonance imaging/spectroscopy (MRI/MRS), will be assessed at baseline and after 28
      days of treatment. Blood pressure will be assessed at baseline and after two weeks of
      treatment. Microvascular function will be assessed with capillary videomicroscopy both at
      baseline and after two weeks of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose tolerance as assessed by the area under the curve for glucose (AUCgluc) during a standardized meal test.</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incretin secretion during standardized meal test</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular function: fasting and postprandial</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition, body fat distribution and intra organ fat accumulation</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular mechanisms in subcutaneous adipose tissue</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure and hemodynamic parameters</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers such as lipoproteins, adipocytokines, and markers of systemic inflammation</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery after cessation of the two-week prednisolone treatment</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta-cell function as determined by hyperglycemic clamp tests and modeling analysis from mixed-meal tests.</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Steroid Diabetes</condition>
  <condition>Glucocorticoid-induced Diabetes</condition>
  <condition>Beta-cell Function</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>prednisolone + sitagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>prednisolone + sitagliptin-placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>prednisolone-placebo + sitagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>prednisolone-placebo + sitagliptin-placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>12 healthy men will be included to assess postprandial microvascular function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 diabetic subjects</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>12 men with type 2 diabetes will be included in order to assess postprandial microvascular function.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin 100 mg</intervention_name>
    <description>28 days administration of 100 mg daily</description>
    <arm_group_label>I</arm_group_label>
    <arm_group_label>III</arm_group_label>
    <other_name>Januvia</other_name>
    <other_name>MK-0431</other_name>
    <other_name>ATC A10BH01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone 30 mg</intervention_name>
    <description>14 days administration of 30 mg daily</description>
    <arm_group_label>I</arm_group_label>
    <arm_group_label>II</arm_group_label>
    <other_name>prednison</other_name>
    <other_name>ATC H02AB06</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin-placebo</intervention_name>
    <description>28 days administration once daily</description>
    <arm_group_label>II</arm_group_label>
    <arm_group_label>IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone-placebo</intervention_name>
    <description>14 days administration once daily</description>
    <arm_group_label>III</arm_group_label>
    <arm_group_label>IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian males

          -  Modified from IDF criteria for the metabolic syndrome:

               -  Waist circumference ≥ 94 cm

          -  And at least 2 or more of the following criteria:

               -  TG ≥ 1.7 mmol/L

               -  HDL cholesterol &lt; 1.03 mmol/L

               -  Blood pressure &gt;130/85 mmHg (average of three measurements) or treatment of
                  previously diagnosed hypertension

               -  Fasting plasma glucose level (FPG) ≥ 5.6 mmol/L (but no diabetes)

        Exclusion Criteria:

          -  An allergic or anaphylactic reaction to prednisolone treatment in the past

          -  Clinically relevant history or presence of any medical disorder, which are mentioned
             in the Summary of Product Characteristics (SPC) as contraindication for the use of
             prednisolone

          -  Glucocorticosteroid use during the last three months prior to the first dose

          -  Participation in an investigational drug trial within 90 days prior to the first dose

          -  Donation of blood ( &gt; 100 mL) within 90 days prior to the first dose

          -  History of or current abuse of drugs or alcohol (&gt;14 U/week)

          -  Use of grapefruit products during the study period

          -  Recent changes in weight and/or physical activity

          -  Serious mental impairment or language problems i.e. preventing to understand the study
             protocol/aim

          -  Diabetes mellitus (defined as FPG ≥ 7.0 mmol/l and/or 2hPG ≥ 11.1 mmol/l)

          -  Serious pulmonary, cardiovascular, hepatic (ALT, AST more than 3x ULN) or renal
             disease (serum creatinine &gt; 135 micromol/L)

          -  History of cardiovascular disease, such as myocardial infarction, cerebrovascular
             accident.

          -  Major psychiatric disorder, depression

          -  All diseases that induce changes in the hypothalamic-pituitary-adrenal (HPA) axis

          -  Malignant disease

          -  All other relevant medical disorders that potentially interfere with this trial.

          -  All medication interfering with study drug or interfering with study
             endpoints/hypotheses
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michaela Diamant, Md PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VUmc Diabetes Center, Amsterdam, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VUmc Diabetes Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2008</study_first_submitted>
  <study_first_submitted_qc>July 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2008</study_first_posted>
  <last_update_submitted>June 28, 2012</last_update_submitted>
  <last_update_submitted_qc>June 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>M. Diamant</investigator_full_name>
    <investigator_title>Prof. M. Diamant</investigator_title>
  </responsible_party>
  <keyword>beta-cell function</keyword>
  <keyword>glucocorticoid-induced diabetes</keyword>
  <keyword>glucocorticoid</keyword>
  <keyword>DPP-4 inhibitors</keyword>
  <keyword>sitagliptin</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>steroid diabetes</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>insulin sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

